Cyclosporine-A is being used increasingly for immunosuppression in patients undergoing organ transplantation. Hepatotoxicity has been noted to occur in up to 20% of renal transplant recipients receiving the drug. The exact nature of this hepato-toxicity, however, has not been defined, although it has been manifested principally, if not exclusively, as elevated serum bilirubin levels. The authors have observed a similar elevation of serum bilirubin levels in cardiac transplant recipients receiving cyclosporine-A and prednisone for immunosuppression.

Cholestasis in heart transplant recipients treated with cyclosporine.

GUGLIELMI, Alfredo;
1983

Abstract

Cyclosporine-A is being used increasingly for immunosuppression in patients undergoing organ transplantation. Hepatotoxicity has been noted to occur in up to 20% of renal transplant recipients receiving the drug. The exact nature of this hepato-toxicity, however, has not been defined, although it has been manifested principally, if not exclusively, as elevated serum bilirubin levels. The authors have observed a similar elevation of serum bilirubin levels in cardiac transplant recipients receiving cyclosporine-A and prednisone for immunosuppression.
transplantation; cyclosporin A; Heart transplantation; cholestasis
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/431658
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact